Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.4622
-0.0182 (-3.79%)
At close: Jan 9, 2026, 4:00 PM EST
0.4622
0.00 (0.00%)
Pre-market: Jan 12, 2026, 8:05 AM EST
Propanc Biopharma Employees
As of June 30, 2025, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$31,703,364
Market Cap
6.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2 | 0 | - |
| Jun 30, 2024 | 2 | 0 | - |
| Jun 30, 2023 | 2 | -1 | -33.33% |
| Jun 30, 2022 | 3 | 1 | 50.00% |
| Jun 30, 2021 | 2 | -1 | -33.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PPCB News
- 21 days ago - Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal - GlobeNewsWire
- 5 weeks ago - Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - GlobeNewsWire
- 5 weeks ago - Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis - GlobeNewsWire
- 7 weeks ago - Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results - GlobeNewsWire
- 2 months ago - Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline - GlobeNewsWire
- 2 months ago - Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) - GlobeNewsWire
- 3 months ago - CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital - GlobeNewsWire
- 3 months ago - Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital - GlobeNewsWire